2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2997

Microrna-29a Curtails Synovitis in the Development of Knee Osteoarthritis By Disrupting VEGF
Abstract Number: 2099

Micrornas As Potential Modulators of Atherothrombosis in Antiphospholipid Syndrome
Abstract Number: 1666

Micrornas Mir-30b-5p, Mir-34a-5p, and Mir-431-3p Are Highly Expressed in the Plasma of Patients with Ankylosing Spondylitis
Abstract Number: 809

Micrornas Targeting the Wnt Signalling Pathway in Black African Patients with Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 2897

Microvascular Function in Systemic Sclerosis Patients with End-Stage Vascular Manifestations of the Disease
Abstract Number: 590

Microvesicles in the Lungs of Early Rheumatoid Arthritis
Abstract Number: 2332

Midterm Outcome of Modular Metal-on-Metal Total Hip Arthroplasty
Abstract Number: 473

Migration, Colonization and Distribution of Bone Marrow Mesenchymal Stem Cells Transplanted in CIA Rats Were Traced By Green Fluorescent Protein
Abstract Number: 1056

Mind-Body Skills Training and Supportive Counseling for Depression in SLE: Positive Effects in a Randomized Controlled Trial
Abstract Number: 300

Mindfulness Predicts Treatment Response from Non-Pharmacological Therapy in Knee Osteoarthritis
Abstract Number: 2085

Minding the Gap: the Use of Nurse Practitioners and Physician Assistants in U.S. Rheumatology Practice to Affect Rheumatology Workforce Shortages
Abstract Number: 1765

Minimal Clinically Important Differences for Generic Patient Reported Outcomes Tools in SLE
Abstract Number: 2767

Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Evaluation of Modified Minimal Disease Activity upon Elimination of Each Component
Abstract Number: 2758

Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria Are More Prevalent Among Responders?
Abstract Number: 1696

Minimal Disease Activity Is a Stable Measure of Therapeutic Response in Psoriatic Arthritis Patients Receiving Treatment with Adalimumab

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].